2016
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology 2016, 2: 1-8. PMID: 26539793, PMCID: PMC5654518, DOI: 10.1001/jamaoncol.2015.3709.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm StagingPaclitaxelReceptor, ErbB-2Risk AssessmentRisk FactorsStroke VolumeTime FactorsTrastuzumabTreatment OutcomeUnited StatesVentricular Dysfunction, LeftVentricular Function, LeftYoung AdultConceptsErbB2-positive breast cancerAsymptomatic LVEF declineCardiac toxic effectsLVEF declineBreast cancerPatients LVEFGrade 3Early-stage human epidermal growth factor receptor 2Asymptomatic left ventricular ejection fraction declineLeft ventricular ejection fraction declineVentricular ejection fraction declineHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Adjuvant weekly paclitaxelCardiac safety dataEjection fraction declineMedian patient ageVentricular systolic dysfunctionTrastuzumab-based treatmentWeeks of chemotherapyGrowth factor receptor 2Positive breast cancerLife-saving therapyFactor receptor 2Single-group study
2010
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress In Cardiovascular Diseases 2010, 53: 94-104. PMID: 20728696, DOI: 10.1016/j.pcad.2010.05.006.Peer-Reviewed Original ResearchConceptsCardiac adverse effectsCardiac toxicityCardiovascular toxicityNew drug developmentLeft ventricular ejection fraction declineVentricular ejection fraction declineAdverse effectsClassic chemotherapy agentsEjection fraction declinePotential cardiovascular toxicityRare serious complicationsNovel biologic agentsSignificant cardiac dysfunctionAcute coronary syndromeCongestive heart failureLong-term complicationsTypes of malignanciesSystemic cancer therapyLife-threatening eventsCancer therapyTyrosine kinase inhibitorsDrug developmentCardiovascular safetyCoronary syndromeBiologic agents